Drug · Small Molecule

Tegafur

CI-DRUG-00000581Explore in graph →NCIt C513 CHEMBL20883 CIViC Approved

Regulatory

Approvals (1)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	—	Teysuno is indicated in adults: - for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1). - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.	approved	Mar 14, 2011	ema

Data updated 14 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	8	5	8	38	1	EU	Mar 14, 2011	1996-04
Malignant Colon Neoplasm	Phase4	Phase 4	0	0	0	2	0	—	—	2014-09
Malignant Gastric Neoplasm	Phase3	Phase 3	4	2	2	7	0	—	—	Mar 1, 2020
Malignant Esophageal Neoplasm	Phase3	Phase 3	3	3	1	4	0	—

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DPYD DPYD*13 HOMOZYGOSITY1
Capecitabine +

Clinical trials

Trials with this intervention (38)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–38 of 38 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06339619	Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma	recruiting	Phase 2	32	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	1	Jun 4, 2026	clinicaltrials
NCT03406299	Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Molecule

Record

Kind: Small Molecule
Mechanism: RNA inhibitor; Thymidylate synthase inhibitor; DNA inhibitor
Targets: 1 gene
Aliases: 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione, 5-Fluoro-1-(tetrahydro-2-furyl)-uracil, Atillon, BMS-200604, Citofur, Coparogin, Exonal, Fental, Florafur, Fluorofur, Franrose, FT, FT-207, Ftorafur, Ftoral, Ftoralon, Fulaid, Fulfeel, Furafluor, Furofutran, Futraful, J356.722B, Lamar, Lifril, MJF-12264, N1-(2'-Furanidyl)-5-fluorouracil, Neberk, Nitobanil, NSC-148958, Riol … (+15)

Data updated 3 hours agoSource updated unknown

Identifiers

Codes (2)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01BC53	Antineoplastic agents
EMA product	EMEA/H/C/001242	Teysuno

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.